Tenaya Therapeutics Files 2025 Annual Report
Ticker: TNYA · Form: ARS · Filed: Apr 16, 2026 · CIK: 0001858848
Sentiment: neutral
Topics: annual-report, sec-filing, biotechnology
Related Tickers: TNYA
TL;DR
Tenaya Therapeutics (TNYA) filed its 2025 ARS on 4/16/26. Check it for FY25 performance.
AI Summary
Tenaya Therapeutics, Inc. filed its Annual Report to Security Holders (ARS) on April 16, 2026, for the period ending December 31, 2025. The report details the company's financial and operational status for the fiscal year 2025. Tenaya Therapeutics, Inc. is a biotechnology company focused on developing therapies for cardiovascular disease.
Why It Matters
This filing provides investors and the public with a comprehensive overview of Tenaya Therapeutics' performance and financial health for the fiscal year 2025, crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine annual filing providing historical information, not a filing that introduces new risks or significant immediate changes.
Key Players & Entities
- Tenaya Therapeutics, Inc. (company) — Filer of the ARS
- 0001858848 (company) — CIK number for Tenaya Therapeutics, Inc.
- 2026-04-16 (date) — Filing date of the ARS
- 2025-12-31 (date) — Period of report for the ARS
FAQ
What is the primary business of Tenaya Therapeutics, Inc.?
Tenaya Therapeutics, Inc. is involved in Biological Products, (No Diagnostic Substances), operating within the Life Sciences sector.
When was the Annual Report to Security Holders (ARS) filed?
The ARS was filed on April 16, 2026.
What period does this ARS filing cover?
This ARS filing covers the period ending December 31, 2025.
What is the CIK number for Tenaya Therapeutics, Inc.?
The CIK number for Tenaya Therapeutics, Inc. is 0001858848.
Where is Tenaya Therapeutics, Inc. located?
Tenaya Therapeutics, Inc. is located at 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080.
Filing Details
This Form ARS (Form ARS) was filed with the SEC on April 16, 2026 regarding Tenaya Therapeutics, Inc. (TNYA).